News

Santa Clara-based Intel is laying off about 25,000 workers. Here's the latest as the semiconductor giant watches its stock ...
The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.
Bristol Myers Squibb acknowledged that a phase III trial of luspatercept (Reblozyl) plus a Janus kinase inhibitor for ...
We thank Sara Osborne and colleagues for their interest in our trial.1 Ligelizumab phase 3 studies in patients with chronic spontaneous urticaria (CSU)1 were done with a study design and in ...
Among reasons for the rejection, the agency cited a lack of US patient representation in the STARGLO trial assessing ...
The latest round of terminations, which will take effect Sept. 15, comes after Genentech fired more than 500 employees in the ...
Patients on Itovebi plus Ibrance and fulvestrant had improved progression-free and overall survival compared to Ibrance-fulvestrant alone.
Genentech has executed another round of layoffs, eliminating 87 positions at its headquarters in South San Francisco. | Genentech has executed another round of layoffs, eliminating 87 positions at its ...
The FDA has decided not to approve glofitamab plus gemcitabine and oxaliplatin to treat certain patients with relapsed/refractory DLBCL.
Oregon Governor Tina Kotek tours Genentech's Hillsboro facility, highlighting innovation and local talent development.
The job cuts include technical and scientific roles and follow multiple rounds of layoffs over the past 18 months.
Roche AG’s Genentech unit disclosed outcomes of two studies testing IL-33-targeting astegolimab vs. placebo on top of standard-of-care maintenance therapy in subjects with moderate to very severe ...